Khanna Anchit, Pimanda John E
Lowy Cancer Research Centre and Prince of Wales Clinical School, University of New South Wales (UNSW) Medicine Department, Sydney, New South Wales, 2052, Australia.
Department of Haematology, the Prince of Wales Hospital, Randwick, New South Wales, Australia.
Int J Cancer. 2016 Feb 1;138(3):525-32. doi: 10.1002/ijc.29431. Epub 2015 Jan 28.
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A), a recently identified oncogene, has emerged as a potential drug target for a range of different tumor types. High CIP2A expression has been reported in almost all solid organ cancers and in some hematological tumors and is associated with high grade and poor prognosis. Notably, high CIP2A expression is determined in over 70% of tumor patient samples in the majority of human cancers. High expression of CIP2A has also been proposed as a useful biomarker that predicts therapeutic response to chemotherapeutics such as Bortezomib, Erlotinib, Checkpoint Kinase 1 inhibitors and pro-senescence based therapies. In this review, we highlight, critically evaluate and discuss the ambiguity in CIP2A's prognostic role in different human cancers and its role in modulating response and resistance to chemotherapeutics.
蛋白磷酸酶2A的癌性抑制剂（CIP2A）是一种最近发现的癌基因，已成为一系列不同肿瘤类型的潜在药物靶点。几乎在所有实体器官癌症以及一些血液肿瘤中都报道了CIP2A的高表达，并且与高分级和不良预后相关。值得注意的是，在大多数人类癌症中，超过70%的肿瘤患者样本中都检测到CIP2A的高表达。CIP2A的高表达也被认为是一种有用的生物标志物，可预测对硼替佐米、厄洛替尼、检查点激酶1抑制剂和基于促衰老的疗法等化疗药物的治疗反应。在这篇综述中，我们重点介绍、批判性评估并讨论了CIP2A在不同人类癌症中的预后作用及其在调节对化疗药物的反应和耐药性方面的作用的模糊性。
